XML 20 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Shares
Treasury Stock
Capital in Excess of Par Value
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   188,560        
Beginning balance at Dec. 31, 2022 $ 366,638 $ 19   $ 3,574,719 $ (6,907) $ (3,201,193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares)   2,824        
Shares issued under equity compensation plans 30     30    
Stock-based compensation 33,388     33,388    
Comprehensive income (loss) $ (269,069)       6,987 (276,056)
Ending balance (in shares) at Dec. 31, 2023 191,384 191,384        
Ending balance at Dec. 31, 2023 $ 130,987 $ 19   3,608,137 80 (3,477,249)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Shares issued under equity compensation plans (in shares)   2,678        
Shares issued under equity compensation plans 118     118    
Stock-based compensation 21,612     21,612    
Repurchase of common stock from Bristol-Myers Squibb (in shares)   (8,285) 8,285      
Repurchase of common stock from Bristol-Myers Squibb (3,000)   $ (3,000)      
Issuance of prefunded warrant 30,000     30,000    
Comprehensive income (loss) $ (118,980)       (19) (118,961)
Ending balance (in shares) at Dec. 31, 2024 185,777 185,777 8,285      
Ending balance at Dec. 31, 2024 $ 60,737 $ 19 $ (3,000) $ 3,659,867 $ 61 $ (3,596,210)